A large number of research institutes as well as 80 private organisations are expected to participate in 'Arogya', a four-day fair on Indian systems of medicine, that begins in Varanasi in Uttar Pradesh.
Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.
A large number of research institutes as well as 80 private organisations are expected to participate in 'Arogya', a four-day fair on Indian systems of medicine, that begins in Varanasi in Uttar Pradesh.
In trying to understand how "female Viagra" will affect the brain of women users, researchers from the University of Wisconsin-Madison have found that when brain metabolism dipped in monkeys during tests, desire went up in them for popping "female Viagra".
Coconut milk has been proved to be the next best to breast milk and the Coconut Development Board (CDB) is set to promote it as a health drink and one to be used for cooking.
India's health system needs an urgent course correction across several key challenges, if the country is to achieve the government's vision of assuring health for all, says a paper in The Lancet.
Scientists have developed a device that electronically stimulates tear production, which will offer hope to sufferers of dry eye syndrome, one of the most common eye afflictions in the world.
-Two new reports say urgent action needed to build on new momentum
-The benefit cost ratio of investing in the scaling up nutrition programmes in India is 34 to 1
-India’s stunting “represents the largest loss of human potential in any country in human history
(BWI); NeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE. This partnership will help NeoBiocon expand its product offerings in the metabolics segment and will immensely benefit diabetics in UAE.
Teva Pharmaceutical Industries Ltd. and Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.
Hetero received the approval for the fixed-dose combination (FDC) Ledipasvir-Sofosbuvir (90mg/400mg) from Drug Controller General of India (DCGI). Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year, to manufacture and market chronic hepatitis C medicines, Hetero is all set to launch the fixed-dose combination therapy ‘Ledipasvir-Sofosbuvir’ for the Indian patients. The product will be available under the brand name ‘Ledisof’ in India.
U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency. Kanuma is produced by Alexion Pharmaceuticals Inc., based in Cheshire, Connecticut.